617 related articles for article (PubMed ID: 27581733)
1. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry.
Henß L; Beck S; Weidner T; Biedenkopf N; Sliva K; Weber C; Becker S; Schnierle BS
Virol J; 2016 Aug; 13(1):149. PubMed ID: 27581733
[TBL] [Abstract][Full Text] [Related]
2. Suramin Inhibits Chikungunya Virus Entry and Transmission.
Ho YJ; Wang YM; Lu JW; Wu TY; Lin LI; Kuo SC; Lin CC
PLoS One; 2015; 10(7):e0133511. PubMed ID: 26208101
[TBL] [Abstract][Full Text] [Related]
3. Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection.
Albulescu IC; White-Scholten L; Tas A; Hoornweg TE; Ferla S; Kovacikova K; Smit JM; Brancale A; Snijder EJ; van Hemert MJ
Viruses; 2020 Mar; 12(3):. PubMed ID: 32191995
[TBL] [Abstract][Full Text] [Related]
4. Curcumin and Boswellia serrata gum resin extract inhibit chikungunya and vesicular stomatitis virus infections in vitro.
von Rhein C; Weidner T; Henß L; Martin J; Weber C; Sliva K; Schnierle BS
Antiviral Res; 2016 Jan; 125():51-7. PubMed ID: 26611396
[TBL] [Abstract][Full Text] [Related]
5. The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection.
Weber C; Sliva K; von Rhein C; Kümmerer BM; Schnierle BS
Antiviral Res; 2015 Jan; 113():1-3. PubMed ID: 25446334
[TBL] [Abstract][Full Text] [Related]
6. Identification of Functional Determinants in the Chikungunya Virus E2 Protein.
Weber C; Berberich E; von Rhein C; Henß L; Hildt E; Schnierle BS
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005318. PubMed ID: 28114368
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection.
Ashbrook AW; Lentscher AJ; Zamora PF; Silva LA; May NA; Bauer JA; Morrison TE; Dermody TS
mBio; 2016 May; 7(3):. PubMed ID: 27222471
[TBL] [Abstract][Full Text] [Related]
8. Suramin inhibits chikungunya virus replication through multiple mechanisms.
Albulescu IC; van Hoolwerff M; Wolters LA; Bottaro E; Nastruzzi C; Yang SC; Tsay SC; Hwu JR; Snijder EJ; van Hemert MJ
Antiviral Res; 2015 Sep; 121():39-46. PubMed ID: 26112648
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic Drugs Inhibit Chikungunya Virus Infection at Different Stages of the Cell Entry Pathway.
Bouma EM; van de Pol DPI; Sanders ID; Rodenhuis-Zybert IA; Smit JM
J Virol; 2020 Jun; 94(13):. PubMed ID: 32321803
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of combination treatment using EGCG and suramin against the chikungunya virus.
Lu JW; Hsieh PS; Lin CC; Hu MK; Huang SM; Wang YM; Liang CY; Gong Z; Ho YJ
Biochem Biophys Res Commun; 2017 Sep; 491(3):595-602. PubMed ID: 28760340
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission.
Wang YM; Lu JW; Lin CC; Chin YF; Wu TY; Lin LI; Lai ZZ; Kuo SC; Ho YJ
Antiviral Res; 2016 Nov; 135():81-90. PubMed ID: 27742486
[TBL] [Abstract][Full Text] [Related]
12. Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo.
Rothan HA; Bahrani H; Abdulrahman AY; Mohamed Z; Teoh TC; Othman S; Rashid NN; Rahman NA; Yusof R
Antiviral Res; 2016 Mar; 127():50-6. PubMed ID: 26794398
[TBL] [Abstract][Full Text] [Related]
13. Identification of entry inhibitors of Ebola virus pseudotyped vectors from a myxobacterial compound library.
Beck S; Henß L; Weidner T; Herrmann J; Müller R; Chao YK; Grimm C; Weber C; Sliva K; Schnierle BS
Antiviral Res; 2016 Aug; 132():85-91. PubMed ID: 27241689
[TBL] [Abstract][Full Text] [Related]
14. Differential Transmission of Antiviral Drug-Resistant Chikungunya Viruses by
Delang L; Yen PS; Vallet T; Vazeille M; Vignuzzi M; Failloux AB
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135220
[TBL] [Abstract][Full Text] [Related]
15. Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV Agents.
Jadav SS; Sinha BN; Hilgenfeld R; Jayaprakash V
Curr Comput Aided Drug Des; 2017 Nov; 13(4):346-361. PubMed ID: 28294048
[TBL] [Abstract][Full Text] [Related]
16. Suramin treatment reduces chikungunya pathogenesis in mice.
Kuo SC; Wang YM; Ho YJ; Chang TY; Lai ZZ; Tsui PY; Wu TY; Lin CC
Antiviral Res; 2016 Oct; 134():89-96. PubMed ID: 27577529
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the potential of baicalin as an antiviral agent for Chikungunya virus infection.
Oo A; Rausalu K; Merits A; Higgs S; Vanlandingham D; Bakar SA; Zandi K
Antiviral Res; 2018 Feb; 150():101-111. PubMed ID: 29269135
[TBL] [Abstract][Full Text] [Related]
18. Bis(benzofuran-thiazolidinone)s and bis(benzofuran-thiazinanone)s as inhibiting agents for chikungunya virus.
Hwu JR; Gupta NK; Tsay SC; Huang WC; Albulescu IC; Kovacikova K; van Hemert MJ
Antiviral Res; 2017 Oct; 146():96-101. PubMed ID: 28830714
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of nobiletin against chikungunya virus in vitro.
Lin SC; Chen MC; Li S; Lin CC; Wang TT
Antivir Ther; 2017; 22(8):689-697. PubMed ID: 28406093
[TBL] [Abstract][Full Text] [Related]
20. Preparation of vesicular stomatitis virus pseudotype with Chikungunya virus envelope protein.
Tong W; Yin XX; Lee BJ; Li YG
Acta Virol; 2015 Jun; 59(2):189-93. PubMed ID: 26104337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
